Skip to content

Effect of Brain Light Therapy on Gait and Balance in People with Parkinson’s Disease

Effect of transcranial photobiomodulation on gait and postural control in people with Parkinson's disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-57gn649
Enrollment
Unknown
Registered
2025-09-29
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

Before applying the Transcranial Photobiomodulation protocol, participants will be randomly assigned to two groups of 20 participants each: (i) Intervention and (ii) Sham. Transcranial Photobiomodulat
100 mW
20 min) three times per week for six weeks, while Group (ii) Sham will also wear the equipment but will receive sham modulation under the same schedule (three times per week for six weeks)
E02.594.540

Sponsors

Pedro Paulo Gutierrez
Lead Sponsor
Universidade Estadual Paulista (UNESP)
Collaborator

Eligibility

Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants with Parkinson’s disease will be recruited from the Physical Activity Program for Patients with Parkinson’s Disease and the local community, based on the following inclusion criteria: (i) a diagnosis of idiopathic Parkinson’s disease made by a neurologist, according to the London Brain Bank criteria, and (ii) classification between stages 1 and 3 on the Hoehn and Yahr scale

Exclusion criteria

Exclusion criteria: Exclusion criteria include: (i) a history of orthopedic and/or visual impairments that prevent compliance with the experimental protocol; (ii) uncontrolled diseases that may affect peripheral sensory functions (e.g., diabetes); (iii) conditions that pose a risk for Transcranial Photobiomodulation, such as structural brain disease, epilepsy, or the use of potentially photosensitizing medications (e.g., imipramine, phenothiazines, lithium, chloroquine, hydrochlorothiazide, tetracycline); (iv) clinical signs of dementia, defined as a Mini-Mental State Examination score below 20; and (v) failure to complete the 18 required modulation/evaluation sessions

Design outcomes

Primary

MeasureTime frame
To evaluate quantitative gait parameters (velocity, step length and width, cadence, gait variability) under single-task and dual-task conditions, assessed before and after the intervention using a 5.74-meter-long pressure-sensor walkway (GAITRite®, CIR Systems Inc., Sparta, USA);To evaluate postural control parameters (sway area, mean amplitude, mean velocity, and mean frequency of center of pressure displacement) under single-task and dual-task conditions, assessed in a static position before and after the intervention using a force platform

Secondary

MeasureTime frame
To evaluate cortical activity recorded before and after the intervention using functional near-infrared spectroscopy (fNIRS), through the analysis of cerebral oxygenation (oxy-Hb and deoxy-Hb) during walking and postural control tasks

Countries

Brazil

Contacts

Public ContactPedro Gutierrez

Universidade Estadual Paulista "Julio de Mesquita Filho"

ppaulogutierrez013@gmail.com+55 (19) 98213-0088

Outcome results

None listed

Source: REBEC (via WHO ICTRP)